Loading...
India's rivaroxaban imports from MEXICO total $19 across 4 shipments from 1 foreign suppliers. MEDA PHARMA S DE RL DE CV leads with $19 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include MYLAN LABORATORIES LIMITED. This corridor reflects India's pharmaceutical import demand for rivaroxaban — a concentrated sourcing relationship with select suppliers from MEXICO.
MEDA PHARMA S DE RL DE CV is the leading Rivaroxaban supplier from MEXICO to India, with import value of $19 across 4 shipments. The top 5 suppliers — MEDA PHARMA S DE RL DE CV — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MEDA PHARMA S DE RL DE CV | $19 | 4 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED | $19 | 4 | 100.0% |
MEXICO → India trade corridor intelligence
The Mexico to India trade corridor for pharmaceutical imports is currently stable. Major ports like Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and the Mexican Peso is favorable for importers. No significant disruptions have been reported in the supply chain, ensuring a reliable flow of Rivaroxaban formulations from Mexico to India.
The Production Linked Incentive (PLI) scheme introduced by the Indian government aims to boost domestic manufacturing and reduce import dependency. While this initiative encourages local production, it may impact the volume of finished formulation imports, including Rivaroxaban. Import substitution policies are being evaluated to balance the need for self-reliance with the demand for imported pharmaceuticals. The impact of these policies on imports from Mexico is yet to be fully determined.
India and Mexico share a growing trade relationship, with ongoing discussions to enhance bilateral trade in pharmaceuticals. Negotiations for a Free Trade Agreement (FTA) are in progress, aiming to reduce trade barriers and facilitate smoother transactions. Mutual recognition of Good Manufacturing Practices (GMP) is being pursued to ensure product quality and safety. These efforts are expected to strengthen pharmaceutical trade between the two nations.
The landed cost of importing Rivaroxaban formulations from Mexico to India includes the following components:
CDSCO registration, import licensing, and quality testing requirements
To import finished pharmaceutical formulations containing Rivaroxaban (HS Code 30049099) into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 40/41 to CDSCO, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory review processes. Rivaroxaban formulations must comply with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945, ensuring they meet India's safety, efficacy, and quality standards.
Imported Rivaroxaban formulations are subject to quality testing by CDSCO-approved laboratories. Each batch must undergo testing to verify compliance with the Indian Pharmacopoeia standards, including assessments of purity, potency, and stability. The Certificate of Analysis (CoA) and stability data (preferably in ICH Zone IV conditions) are mandatory for import clearance. Port inspections by customs drug inspectors are conducted to ensure adherence to regulatory requirements. If a batch fails quality testing, it may be rejected, leading to potential delays or additional costs for the importer.
Between 2024 and 2026, CDSCO has implemented stricter regulations for importing pharmaceutical products, including mandatory import registration and licensing for all drugs. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and Mexico have focused on mutual recognition of Good Manufacturing Practices (GMP), facilitating smoother trade in pharmaceutical products.
Market demand, customs duty structure, and competitive landscape · Import duty: 17.10%
India imports finished Rivaroxaban formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as extended-release tablets, may not be produced locally, necessitating imports. The market size for Rivaroxaban in India is substantial, driven by its use in treating conditions like atrial fibrillation and deep vein thrombosis. Despite domestic production, imports remain essential to fulfill the diverse needs of the Indian market.
The import duty structure for Rivaroxaban formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, a Secondary Higher Education Cess of 1%, and a Social Welfare Surcharge (SWS) of 10%. The Integrated Goods and Services Tax (IGST) is applicable at 12%. There are no additional duties such as Anti-Dumping Duty or National Calamity Contingent Duty (NCCD) for this product. Exemptions or concessional rates are not available for imports from Mexico.
India sources Rivaroxaban formulations from Mexico due to the availability of specialized dosage forms and formulations not produced domestically. Mexico's pharmaceutical industry offers high-quality products that meet international standards, providing a competitive advantage in terms of quality and reliability. Other suppliers, such as China, Germany, and the United States, also export Rivaroxaban formulations to India, but Mexico's unique offerings and established trade relations position it favorably in the Indian market.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Rivaroxaban formulations from Mexico due to the availability of specialized dosage forms and formulations not produced domestically. Mexico's pharmaceutical industry offers high-quality products that meet international standards, providing a competitive advantage in terms of quality and reliability. The established trade relations and favorable exchange rates further enhance the attractiveness of sourcing from Mexico.
When compared to other origins such as China, Germany, and the United States, Mexico offers competitive pricing and high-quality Rivaroxaban formulations. While China may offer lower prices, concerns about quality and regulatory compliance can be a drawback. Germany and the United States provide high-quality products but at higher prices. Mexico's unique advantage lies in its ability to offer quality formulations at competitive prices, with established trade relations and favorable exchange rates.
Potential risks for Indian importers include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider dual-sourcing strategies, maintain adequate inventory levels, and establish strong relationships with suppliers. Regular monitoring of regulatory changes and market conditions is essential to anticipate and address potential challenges.
Import license checklist, document requirements, quality testing, and compliance
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Rivaroxaban suppliers from MEXICO to India include MEDA PHARMA S DE RL DE CV. The leading supplier is MEDA PHARMA S DE RL DE CV with import value of $19 USD across 4 shipments. India imported Rivaroxaban worth $19 USD from MEXICO in total across 4 shipments.
India imported Rivaroxaban worth $19 USD from MEXICO across 4 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Rivaroxaban sourced from MEXICO include MYLAN LABORATORIES LIMITED. The largest buyer is MYLAN LABORATORIES LIMITED with $19 in imports across 4 shipments.
The total value of Rivaroxaban imports from MEXICO to India is $19 USD, across 4 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
4 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists